Bcr-Abl tyrosine kinase inhibitors- current status

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Bcr-Abl oncoprotein drives chromosome-positive leukaemias, causing increased cell proliferation and apoptosis resistance.
• Imatinib was the first Bcr-Abl tyrosine kinase inhibitor, followed by second-generation drugs like Nilotinib and Dasatinib.
• Newer inhibitors such as Ponatinib and Bafetinib target specific Bcr-Abl mutations, while thiadiazole derivatives show broader kinase inhibition.

Purpose of the Study:

• To review the landscape of Bcr-Abl tyrosine kinase inhibitors.
• To highlight the efficacy and positioning of Nilotinib in chronic myeloid leukaemia treatment.
• To discuss the development of resistance and intolerance to imatinib and the role of subsequent-generation inhibitors.

Main Methods:

• Literature review of Bcr-Abl tyrosine kinase inhibitors.
• Analysis of drug efficacy against Bcr-Abl positive leukaemias.
• Comparison of resistance and intolerance profiles of different inhibitors.

Main Results:

• Imatinib, Nilotinib, Dasatinib, Ponatinib, and Bafetinib are key Bcr-Abl inhibitors.
• Second-generation inhibitors aim to overcome imatinib resistance and intolerance.
• Ponatinib and Bafetinib are effective against various Bcr-Abl point mutations.
• Thiadiazole derivatives exhibit moderate inhibitory activity against Abl and Src kinases.

Conclusions:

• Nilotinib is currently the frontline tyrosine kinase inhibitor for Bcr-Abl positive leukaemias.
• The development of Bcr-Abl inhibitors has progressed to address resistance and intolerance.
• Ongoing research explores novel inhibitors and therapeutic strategies for leukaemias.